Source: Bio-Sourcing | Sep 24, 2024

Bio-Sourcing secures European Innovation Council (EIC) Accelerator funding to bridge the biomanufacturing gap and make biotherapeutics more available and affordable

The first biosimilar the company will bring to trials is adalimumab (Humira), a widely used treatment for autoimmune diseases

The funding – a €2.5M grant and additional €10M in equity - shows clear recognition of the ability of Bio-Sourcing’s (www.Bio-Sourcing.com) technical platform to impart changes on biomanufacturing sovereignty and to increase access to cutting-edge pharmaceuticals treatments, such as biosimilars; The BioMilk platform allows large volume production with limited capital expenditure…